Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Core Insights - Lipocine Inc. announced that its candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology, indicating its potential as a "First in Class" product for hepatic encephalopathy and sarcopenia [1][3] - The Phase 2 trial results for LPCN 1148 were published in the same issue, showcasing its efficacy and safety in treating cirrhosis patients [2][9] - The US FDA has granted fast track designation to LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis, highlighting its significance in addressing unmet medical needs [4][11] Company Overview - Lipocine is a biopharmaceutical company focused on developing therapeutics with effective oral delivery, targeting significant unmet medical needs in various conditions [12] - The company is exploring partnerships for LPCN 1148 and other drug candidates, aiming to enhance patient outcomes and quality of life for those with liver diseases [4][12][13] Industry Context - Cirrhosis is a severe liver disease affecting over 382,000 patients in the US, with limited treatment options available, primarily liver transplantation [6][5] - Hepatic encephalopathy is a common and debilitating complication of cirrhosis, with a high recurrence rate and significant impact on patient quality of life [7][8] - The need for effective treatments for sarcopenia and hepatic encephalopathy in cirrhosis patients is critical, as current management options are limited to diet and exercise [3][5]